Preview Mode Links will not work in preview mode

GRACEcast


Jan 26, 2013

Dr. Jack West reviews the encouraging results with selumetinib, a MEK inhibitor, in combination with chemotherapy for patients with advanced NSCLC and a KRAS mutation, the most common molecular marker seen in lung cancer.